Back to discover
Drug

Urelumab

In clinical development
ClassTumor necrosis factor receptor superfamily member 9 agonistEmerging researchEarly-to-mid development
RxNorm1967872ChEMBLCHEMBL1743085UNII230902QLLC
1
Research papers
1
Active clinical trials
TNFRSF9
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas

Clinical trial2026-06-01Results expected Q3 2026 · ClinicalTrials.gov

Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors

Clinical trial2022-04-11Completed · ClinicalTrials.gov

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma

Clinical trial2019-05-24Terminated · ClinicalTrials.gov

A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Clinical trial2017-10-10Completed · ClinicalTrials.gov

Urelumab (CD137 mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Clinical trial2016-12-06Withdrawn · ClinicalTrials.gov

A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck

Clinical trial2016-12-01Completed · ClinicalTrials.gov

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors

Clinical trial2016-11-11Completed · ClinicalTrials.gov

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Research2016-10-18Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies

Clinical trial2016-08-01Completed · ClinicalTrials.gov

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Clinical trial2016-04-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Urelumab
RxNorm CUI
1967872
ChEMBL ID
CHEMBL1743085
UNII
230902QLLC
Primary mechanism
Tumor necrosis factor receptor superfamily member 9 agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Tumor necrosis factor receptor superfamily member 9
TNFRSF9 · Q07011
AGONISTTumor necrosis factor receptor superfamily member 9 agonist

Clinical trials

9 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
9
registered trials across all phases
LATEST COMPLETION 2022
1
Active studies
6
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 9
Phase 16Phase 1 / 21Phase 22

Recent completions

Trials that read out recently, adding to the completed evidence base.

Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors

CompletedPH IUniversity of Chicagon=602022

A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

CompletedPH IBristol-Myers Squibbn=442017

A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck

CompletedPH IBristol-Myers Squibbn=662016

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors

CompletedPH IBristol-Myers Squibbn=182016

A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies

CompletedPH IBristol-Myers Squibbn=472016

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

CompletedPH IBristol-Myers Squibbn=1242016

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2017 · 313 cites
Recent papers

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2017 · 313 cites
Journals, researchers & institutions
Top journals
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
Leading researchers
  • Ascierto PA1
  • Chiarion-Sileni V1
  • Gangadhar TC1
  • Hamid O1
  • Hodi FS1
  • Jure-Kunkel M1
  • Kohrt H1
  • Krishnan S1
Leading institutions
free-text, unnormalised
  • Aarhus University Hospital1
  • Abramson Cancer Center of the University of Pennsylvania1
  • Beth Israel Deaconess Medical Center1
  • Clinica Universidad de Navarra1
  • Dana-Farber Cancer Institute1
  • Earle A. Chiles Research Institute1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials